Cimon Medical is the owner of a unique proprietary technology for continuous monitoring of blood-flow using non-invasive Doppler ultrasound. The core of the innovation is a coin-sized ultrasound probe constructed as a single element transducer with an unfocused beam that can measure blood circulation continuously by illuminating a 1×4 cm cylindric area of the tissue and capture all blood flow signals in this volume simultaneously. From clinical research using this equipment, it has become clear that relative measures of blood volume flow within a region can be obtained with much simpler equipment than an absolute measure but be just as valuable. This circumvents the problem that has stumped previous attempts at continuous blood flow monitoring: attempting to establish an absolute measure in a single blood vessel. This means that there is no need for expensive transducers, complex processing systems, or skilled operators.
This type of monitoring has not been possible before
The main benefits of the Cimon technology compared to existing solutions are:
- Direct and continuous measurement of blood-flow.
- Immediate response to events.
- Non-invasive, easy to use and does not require trained personnel to operate.
- Affordable – low cost
The scalability of the technology enables development of multiple products within different areas of medicine where early and accurate recognition of on-going blood flow disturbances could be the key to preventing damage, improving treatment strategies and reducing societal health costs, with the potential to develop new Standards of Care.
Some of them are:
- Measurement of fetal wellbeing during delivery to support timely intervention decisions and avoid adverse events.
- Detection of brain blood-flow in patients undergoing interventtions or surgery.
- Confirmation of reestablished blood-flow to the brain in emergency situations after cardiac arrest (during Cardiac Pulmonary Resuscitation).
- Monitoring of peripheral circulation to support diagnosis of chronic arterial insufficiency and predict outcome of therapeutic interventions.
- Detection of early changes in peripheral microcirculation in Sepsis to assist in-time treatment decisions.
With this wide range of application- and product possibilities we are seeking partnerships in order to bring the Cimon technology to market.
System architecure designed to support development of new products/applications with minimal additional investment.
Multiple markets/application segments
Cimon technology is already being used routinely in clinical research and has been demonstrated in a number of clinical applications
Flexible system adaption
Cimon technology is well suited for integration with third-party systems, such as patient-monitoring solutions (OEM).
Applicable in multiple settings
The Cimon Technology is also applicable outside a hospital setting, in ambulant emergency services or for personalized home-based monitoring
Sepsis is a bacterial infection with high mortality. Globally, 120 million people develop severe infections each year. In 30 million of these cases, the infection progresses to sepsis. 30 % of these patients eventually die of the infection. Accurately sepsis diagnosis at an early stage is critical as the risk of death increases with every passing hour the condition goes untreated. Despite this, there are currently no diagnostic tools for early detection of sepsis.
Changes in micro circulation is an early indicator of sepsis development. Using a new, non-invasive, ultrasound probe and application specific signal analysis, our technology enables early detection of sepsis through continuous monitoring of microcirculation. This enables early medical intervention with antibiotics. The technology is operator independent and does not require ultrasound expertise.
A feasibility study with 4 patients was completed during spring 2018. The study verified the CIMON Medical technology against established methods. Two further are initiated at St. Olav’s Hospital.
Peripheral arterial disease (PAD) is a disease leading to tissue damage, foot ulcers, and amputation. The disease is caused by occlusion of the arteries and is commonly treated with surgery to remove occlusions. In 2010, 202 million people around the world were living with PAD. Currently, there is no simple, user-independent tool for detection of initial occlusion in the arteries, nor tools for detecting complications after surgery.
Using a new non-invasive ultrasound probe and application specific signal analysis, our technology enables both early diagnosis of PAD as well as complication detection after surgery. The technology can also be used as a tool for decision support during surgical treatment of PAD. The technology is operator independent and does not require ultrasound expertise.
A feasibility study with 10 patients was completed during the spring of 2017. The study verified the CIMON Medical technology against established methods. Three further studies are initiated at St. Olav’s Hospital, Oslo University Hospital, and Hospital of Southern Norway.